Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TT8H9GB)

• DTT Name: MEK2 messenger RNA (MEK2 mRNA)
• Synonyms: PRKMK2 (mRNA); MKK2 (mRNA); MEK 2 (mRNA); MAPKK 2 (mRNA); MAPK/ERK kinase 2 (mRNA); MAP kinase kinase 2 (mRNA); Dual specificity mitogenactivated protein kinase kinase 2 (mRNA); Dual specificity mitogen-activated protein kinase kinase 2 (mRNA)
• Gene Name: MAP2K2
• DTT Type: Literature-reported target; [1]
• BioChemical Class: mRNA target
• UniProt ID: MP2K2_HUMAN
• TTD ID: T31032
• EC Number: EC 2.7.12.2
• Sequence:
  MLARRKPVLPALTINPTIAEGPSPTSEGASEANLVDLQKKLEELELDEQQKKRLEAFLTQ
  KAKVGELKDDDFERISELGAGNGGVVTKVQHRPSGLIMARKLIHLEIKPAIRNQIIRELQ
  VLHECNSPYIVGFYGAFYSDGEISICMEHMDGGSLDQVLKEAKRIPEEILGKVSIAVLRG
  LAYLREKHQIMHRDVKPSNILVNSRGEIKLCDFGVSGQLIDSMANSFVGTRSYMAPERLQ
  GTHYSVQSDIWSMGLSLVELAVGRYPIPPPDAKELEAIFGRPVVDGEEGEPHSISPRPRP
  PGRPVSGHGMDSRPAMAIFELLDYIVNEPPPKLPNGVFTPDFQEFVNKCLIKNPAERADL
  KMLTNHTFIKRSEVEEVDFAGWLCKTLRLNQPGTPTRTAV
• Function: Activates the ERK1 and ERK2 MAP kinases. Catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases.
• KEGG Pathway:
  MAPK signaling pathway (hsa04010)
  ErbB signaling pathway (hsa04012)
  Ras signaling pathway (hsa04014)
  Rap1 signaling pathway (hsa04015)
  cGMP-PKG signaling pathway (hsa04022)
  cAMP signaling pathway (hsa04024)
  HIF-1 signaling pathway (hsa04066)
  FoxO signaling pathway (hsa04068)
  Sphingolipid signaling pathway (hsa04071)
  PI3K-Akt signaling pathway (hsa04151)
  Vascular smooth muscle contraction (hsa04270)
  VEGF signaling pathway (hsa04370)
  Gap junction (hsa04540)
  Signaling pathways regulating pluripotency of stem cells (hsa04550)
  Toll-like receptor signaling pathway (hsa04620)
  Natural killer cell mediated cytotoxicity (hsa04650)
  T cell receptor signaling pathway (hsa04660)
  B cell receptor signaling pathway (hsa04662)
  Fc epsilon RI signaling pathway (hsa04664)
  Long-term potentiation (hsa04720)
  Neurotrophin signaling pathway (hsa04722)
  Long-term depression (hsa04730)
  Regulation of actin cytoskeleton (hsa04810)
  Insulin signaling pathway (hsa04910)
  GnRH signaling pathway (hsa04912)
  Estrogen signaling pathway (hsa04915)
  Melanogenesis (hsa04916)
  Prolactin signaling pathway (hsa04917)
  Thyroid hormone signaling pathway (hsa04919)
  Oxytocin signaling pathway (hsa04921)
  Prion diseases (hsa05020)
  Hepatitis B (hsa05161)
  Influenza A (hsa05164)
  Pathways in cancer (hsa05200)
  Proteoglycans in cancer (hsa05205)
  MicroRNAs in cancer (hsa05206)
  Renal cell carcinoma (hsa05211)
  Endometrial cancer (hsa05213)
  Glioma (hsa05214)
  Prostate cancer (hsa05215)
  Thyroid cancer (hsa05216)
  Melanoma (hsa05218)
  Bladder cancer (hsa05219)
  Chronic myeloid leukemia (hsa05220)
  Acute myeloid leukemia (hsa05221)
  Non-small cell lung cancer (hsa05223)
  Central carbon metabolism in cancer (hsa05230)
  Choline metabolism in cancer (hsa05231)
• Reactome Pathway:
  Uptake and function of anthrax toxins (R-HSA-5210891)
  RAF activation (R-HSA-5673000)
  MAP2K and MAPK activation (R-HSA-5674135)
  Negative feedback regulation of MAPK pathway (R-HSA-5674499)
  MAPK1 (ERK2) activation (R-HSA-112411)

Molecular Interaction Atlas (MIA) of This DTT

20 Investigative Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ISIS 25073	DMUMEST	Discovery agent	N.A.	Investigative	[1]
ISIS 25074	DMM0GUN	Discovery agent	N.A.	Investigative	[1]
ISIS 25075	DM1EPLC	Discovery agent	N.A.	Investigative	[1]
ISIS 25078	DMSZRY0	Discovery agent	N.A.	Investigative	[1]
ISIS 25079	DMAKTCH	Discovery agent	N.A.	Investigative	[1]
ISIS 25080	DMEI28S	Discovery agent	N.A.	Investigative	[1]
ISIS 25081	DM4AZG9	Discovery agent	N.A.	Investigative	[1]
ISIS 25082	DM04CUL	Discovery agent	N.A.	Investigative	[1]
ISIS 25113	DM3IR7W	Discovery agent	N.A.	Investigative	[1]
ISIS 25114	DMG6SYP	Discovery agent	N.A.	Investigative	[1]
ISIS 25115	DMDH943	Discovery agent	N.A.	Investigative	[1]
ISIS 25116	DM8AHJC	Discovery agent	N.A.	Investigative	[1]
ISIS 25117	DMAN94P	Discovery agent	N.A.	Investigative	[1]
ISIS 25118	DMA7KV8	Discovery agent	N.A.	Investigative	[1]
ISIS 25123	DMFQO21	Discovery agent	N.A.	Investigative	[1]
ISIS 25124	DMEI8L2	Discovery agent	N.A.	Investigative	[1]
ISIS 25125	DML2F3N	Discovery agent	N.A.	Investigative	[1]
ISIS 25126	DM8K4DP	Discovery agent	N.A.	Investigative	[1]
ISIS 25127	DM6AQ2X	Discovery agent	N.A.	Investigative	[1]
ISIS 25128	DMH3C01	Discovery agent	N.A.	Investigative	[1]

References

• [1] US patent application no. 5,959,097, Antisense modulation of MEK2 expression.